A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis

THE EDARAVONE (MCI-186) ALS 16 STUDY GROUP

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Our first phase III study failed to demonstrate efficacy of edaravone for amyotrophic lateral sclerosis (ALS) compared to placebo. Here, we performed post-hoc subgroup analysis to identify a subgroup in which edaravone might be expected to show efficacy. We focussed on two newly defined subgroups, EESP and dpEESP2y. The EESP was defined as the efficacy-expected subpopulation with % forced vital capacity of ≥80%, and ≥2 points for all item scores in the revised ALS functional rating scale (ALSFRS-R) score before treatment. The dpEESP2y was defined as the greater-efficacy-expected subpopulation within EESP having a diagnosis of ‘definite’ or ‘probable’ ALS according to the El Escorial revised Airlie House diagnostic criteria and onset of disease within two years. The primary endpoint of the post-hoc analysis was the change in the ALSFRS-R score during the 24-week treatment period. The intergroup differences of the least-squares mean change in the ALSFRS-R score ± standard error during treatment were 0.65 ± 0.78 (p = 0.4108) in the full analysis set, 2.20 ± 1.03 (p = 0.0360) in the EESP, and 3.01 ± 1.33 (p = 0.0270) in the dpEESP2y. Edaravone exhibited efficacy in the dpEESP2y subgroup. A further clinical study in patients meeting dpEESP2y criteria is warranted.

Original languageEnglish
Pages (from-to)11-19
Number of pages9
JournalAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Volume18
DOIs
Publication statusPublished - Oct 31 2017

Fingerprint

Amyotrophic Lateral Sclerosis
Vital Capacity
Least-Squares Analysis
Therapeutics
Placebos
Clinical Studies
phenylmethylpyrazolone

Keywords

  • Amyotrophic lateral sclerosis (ALS)
  • edaravone
  • MCI-186
  • revised ALS functional rating scale (ALSFRS-R)
  • subgroup analysis

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis. / THE EDARAVONE (MCI-186) ALS 16 STUDY GROUP.

In: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, Vol. 18, 31.10.2017, p. 11-19.

Research output: Contribution to journalArticle

@article{5cb847515ef54db38856c45149589c05,
title = "A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis",
abstract = "Our first phase III study failed to demonstrate efficacy of edaravone for amyotrophic lateral sclerosis (ALS) compared to placebo. Here, we performed post-hoc subgroup analysis to identify a subgroup in which edaravone might be expected to show efficacy. We focussed on two newly defined subgroups, EESP and dpEESP2y. The EESP was defined as the efficacy-expected subpopulation with {\%} forced vital capacity of ≥80{\%}, and ≥2 points for all item scores in the revised ALS functional rating scale (ALSFRS-R) score before treatment. The dpEESP2y was defined as the greater-efficacy-expected subpopulation within EESP having a diagnosis of ‘definite’ or ‘probable’ ALS according to the El Escorial revised Airlie House diagnostic criteria and onset of disease within two years. The primary endpoint of the post-hoc analysis was the change in the ALSFRS-R score during the 24-week treatment period. The intergroup differences of the least-squares mean change in the ALSFRS-R score ± standard error during treatment were 0.65 ± 0.78 (p = 0.4108) in the full analysis set, 2.20 ± 1.03 (p = 0.0360) in the EESP, and 3.01 ± 1.33 (p = 0.0270) in the dpEESP2y. Edaravone exhibited efficacy in the dpEESP2y subgroup. A further clinical study in patients meeting dpEESP2y criteria is warranted.",
keywords = "Amyotrophic lateral sclerosis (ALS), edaravone, MCI-186, revised ALS functional rating scale (ALSFRS-R), subgroup analysis",
author = "{THE EDARAVONE (MCI-186) ALS 16 STUDY GROUP} and Koji Abe and Koji Abe and Shoji Tsuji and Gen Sobue and Masashi Aoki and Manabu Doyu and Chikuma Hamada and Masanori Togo and Takatomo Yoneoka and Masahiko Tanaka and Makoto Akimoto and Kazue Nakamura and Fumihiro Takahashi and Kazuoki Kondo and Hiide Yoshino",
year = "2017",
month = "10",
day = "31",
doi = "10.1080/21678421.2017.1363780",
language = "English",
volume = "18",
pages = "11--19",
journal = "Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration",
issn = "2167-8421",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis

AU - THE EDARAVONE (MCI-186) ALS 16 STUDY GROUP

AU - Abe, Koji

AU - Abe, Koji

AU - Tsuji, Shoji

AU - Sobue, Gen

AU - Aoki, Masashi

AU - Doyu, Manabu

AU - Hamada, Chikuma

AU - Togo, Masanori

AU - Yoneoka, Takatomo

AU - Tanaka, Masahiko

AU - Akimoto, Makoto

AU - Nakamura, Kazue

AU - Takahashi, Fumihiro

AU - Kondo, Kazuoki

AU - Yoshino, Hiide

PY - 2017/10/31

Y1 - 2017/10/31

N2 - Our first phase III study failed to demonstrate efficacy of edaravone for amyotrophic lateral sclerosis (ALS) compared to placebo. Here, we performed post-hoc subgroup analysis to identify a subgroup in which edaravone might be expected to show efficacy. We focussed on two newly defined subgroups, EESP and dpEESP2y. The EESP was defined as the efficacy-expected subpopulation with % forced vital capacity of ≥80%, and ≥2 points for all item scores in the revised ALS functional rating scale (ALSFRS-R) score before treatment. The dpEESP2y was defined as the greater-efficacy-expected subpopulation within EESP having a diagnosis of ‘definite’ or ‘probable’ ALS according to the El Escorial revised Airlie House diagnostic criteria and onset of disease within two years. The primary endpoint of the post-hoc analysis was the change in the ALSFRS-R score during the 24-week treatment period. The intergroup differences of the least-squares mean change in the ALSFRS-R score ± standard error during treatment were 0.65 ± 0.78 (p = 0.4108) in the full analysis set, 2.20 ± 1.03 (p = 0.0360) in the EESP, and 3.01 ± 1.33 (p = 0.0270) in the dpEESP2y. Edaravone exhibited efficacy in the dpEESP2y subgroup. A further clinical study in patients meeting dpEESP2y criteria is warranted.

AB - Our first phase III study failed to demonstrate efficacy of edaravone for amyotrophic lateral sclerosis (ALS) compared to placebo. Here, we performed post-hoc subgroup analysis to identify a subgroup in which edaravone might be expected to show efficacy. We focussed on two newly defined subgroups, EESP and dpEESP2y. The EESP was defined as the efficacy-expected subpopulation with % forced vital capacity of ≥80%, and ≥2 points for all item scores in the revised ALS functional rating scale (ALSFRS-R) score before treatment. The dpEESP2y was defined as the greater-efficacy-expected subpopulation within EESP having a diagnosis of ‘definite’ or ‘probable’ ALS according to the El Escorial revised Airlie House diagnostic criteria and onset of disease within two years. The primary endpoint of the post-hoc analysis was the change in the ALSFRS-R score during the 24-week treatment period. The intergroup differences of the least-squares mean change in the ALSFRS-R score ± standard error during treatment were 0.65 ± 0.78 (p = 0.4108) in the full analysis set, 2.20 ± 1.03 (p = 0.0360) in the EESP, and 3.01 ± 1.33 (p = 0.0270) in the dpEESP2y. Edaravone exhibited efficacy in the dpEESP2y subgroup. A further clinical study in patients meeting dpEESP2y criteria is warranted.

KW - Amyotrophic lateral sclerosis (ALS)

KW - edaravone

KW - MCI-186

KW - revised ALS functional rating scale (ALSFRS-R)

KW - subgroup analysis

UR - http://www.scopus.com/inward/record.url?scp=85029211000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029211000&partnerID=8YFLogxK

U2 - 10.1080/21678421.2017.1363780

DO - 10.1080/21678421.2017.1363780

M3 - Article

C2 - 28872917

AN - SCOPUS:85029211000

VL - 18

SP - 11

EP - 19

JO - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

JF - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

SN - 2167-8421

ER -